DGAP-News: MOLOGEN AG: Resolved reverse share split implemented

Press release No. 15/2018 on 17 July 2018

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

MOLOGEN AG: Resolved reverse share split implemented

Berlin, 17 July 2018 - Biopharmaceutical Company MOLOGEN AG today announced that the reverse share split in a ratio of 5:1 resolved at the Company's Annual General Meeting on 8 June 2018 has been entered in the Commercial Register. In addition to calling in four no-par shares to even out the existing share capital, stock will now be consolidated. This results in the number of shares issued of 37,686,439 shares being reduced to 7,537,287 shares. The Company's new share capital amounts to EUR7,537,287, divided into 7,537,287 bearer shares. The final trading day for shares with the ISIN DE0006637200 (SIN: 663720) will be presumably on 17 July 2018. The converted bearer shares will be traded on the Frankfurt Stock Exchange under the new ISIN, DE000A2LQ900 (SIN: A2L Q90), presumably from 18 July 2018 onwards. Securities held in the portfolios of shareholders will automatically be switched by the custodian bank.

The reduction in capital and stock consolidation has no significant impact on the assets of shareholders. They do not change the capital structure and overall value of MOLOGEN AG. In technical terms, the capital reduction is made possible by offsetting accumulated losses against capital reserves. The aim of this measure is to achieve a balance sheet loss adjustment and secure MOLOGEN AG's capability of being financed. As a result of the share consolidation, MOLOGEN is again financially viable and the already agreed financing instruments can be further implemented.

For each five old no-par shares with a proportional amount in the share capital of EUR1.00 (ISIN: DE0006637200, SIN: 663720), shareholders will receive one converted share with a proportional amount in the share capital of EUR1.00 (ISIN: DE000A2LQ900, SIN: A2L Q90). To keep the financial impact of technical, unavoidable fractions to a minimum for shareholders, the Company will make arrangements which are usual in the market so that custodian banks will endeavor, on customers' instructions, to settle fractions by buying additional or selling fractional interests. In the event of a settlement of fractions not being possible, any residual fractions will be taken off the books as worthless. This amounts to a maximum of four shares per shareholder and thus to a value-based amount of (currently) around EUR3.50 per shareholder. A refund of fees on the part of the Company is not planned. Shareholders will not incur any costs or charges as a result of the consolidation of old shares, the conversion of portfolio holdings and the settlement of fractions.

Important note:
This announcement is not an offer of securities for sale in the United States, Australia, Canada, Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this press release have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offering of the securities in the United States of America. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan.

MOLOGEN AG
MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.
The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM^(R).

The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in small cell lung cancer have been announced in April 2017, and the final analysis in the first quarter 2018 confirmed the data. Furthermore, data from the extension phase of the TEACH study in HIV have also been published in 2017. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy^(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.

www.mologen.com

Contact

Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.